David Protein Says ‘Diet’ Trends Are Over, GLP-1s Upend Markets
David Rahal, founder and CEO of David Protein, argues GLP-1 drugs have upended the diet-trend cycle, reshaping how br...
Weight Loss tag pages pull together 4 recent articles on stocks, GLP-1 drugs, and market trends to help you evaluate risks and opportunities for your portfolio.
9 articlesDavid Rahal, founder and CEO of David Protein, argues GLP-1 drugs have upended the diet-trend cycle, reshaping how br...
Viking Therapeutics sits at the intersection of biotech risk and big growth potential. This article breaks down what ...
A new wave of weight-loss therapies aims to beat current GLP-1 drugs by reducing side effects and daily dosing. Inves...
A policy push to cover GLP-1 drugs for weight loss under Medicare stalled, leaving many beneficiaries in the middle. ...
The race to own the GLP-1 weight loss market has a new challenger in Viking Therapeutics. This article breaks down wh...
As GLP-1 therapies reshape obesity treatment, investors eye the best weight loss drug stock bets for 2026. This guide...
The launch of oral Wegovy marked a turning point for weight-loss drugs and stock investors. But a newer, rival oral G...
Noom is shifting from psychology-based weight loss to prescription treatments, launching Noom Med in a multi-state ro...
The weight loss field is heating up, with Novo Nordisk leading the GLP-1 wave and Amgen pursuing a smaller, more sele...